뒤로
Alto Neuroscience Inc(ANRO) 가격
ANRO 주가 차트
ANRO 수입
Alto Neuroscience Inc
$24.29
9.11%
$2.02
종가: Mar 16, 16:00:00 GMT-4
$24.49
0.82%
$0.19
프리마켓: Mar 17, 08:37:27 GMT-4
최신 수익 결과: Q3 '25
보고됨: 2025-11-12
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
ANRO의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Alto Neuroscience Inc ANRO의 지난 분기 매출 실적은 어땠나요?
Alto Neuroscience Inc의 매출 추정치는 얼마인가요?
Alto Neuroscience Inc의 수익 품질 점수는 얼마인가요?
Alto Neuroscience Inc는 언제 수익을 보고하나요?
Alto Neuroscience Inc의 예상 수익은 얼마인가요?
Alto Neuroscience Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$22.26
시가
$22.38
일일 범위
$21.76 - $25.12
52주 범위
$1.6 - $24.49
거래량
751.1K
평균 거래량
261.5K
EPS(TTM)
-2.31
배당수익률
--
시가총액
$760.9M
ANRO란 무엇인가요?
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. The company is headquartered in Mountain View, California and currently employs 76 full-time employees. The company went IPO on 2024-02-02. The firm's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.